Date: 2017-12-07
Type of information: Development agreement
Compound: gamma delta CAR T cells
Company: Bluebird bio (USA - MA) TC BioPharm (UK)
Therapeutic area: Cancer - Oncology
Type agreement: research - development - R&D
Action mechanism:
- cell therapy/immunotherapy product/CAR-T cell therapy.
Disease: hematological cancers, solid tumors
Details:
- • On December 7, 2017, bluebird bio and TC BioPharm announced a strategic collaboration and license agreement focused on gamma delta CAR T cells. The companies will work together to advance TC BioPharm’s lead CAR-engineered gamma delta T cell program into clinical trials as well as on additional hematologic and solid tumor targets.
- Under the terms of the agreement, bluebird bio and TCB will collaborate to discover and develop CAR-engineered gamma delta T cells for cancer targets and indications. TCB is responsible for development of all targets through Phase 1/2, at which point bluebird has the exclusive option to assume sole responsibility for further clinical development and commercialization on a global basis.
Financial terms:
- Financial terms of the agreement include a $16 million upfront payment and subsequent potential R&D and commercial milestone payments. TCB is also eligible to receive undisclosed tiered royalties on product sales.
Latest news:
Is general: Yes
